J Korean Med Sci.  2024 Oct;39(41):e263. 10.3346/jkms.2024.39.e263.

Long-Term Outcomes of COVID-19 and Risk Factors for Prolonged or Persistent COVID-19 in Lymphoma Patients: A Multicenter, Retrospective Cohort Study

• Lee JA
• Han M
• Ahn S
• Lee Y
• Yeom JS
• Choi JY
• Ku NS
• Jeong SJ
• Kim JH
• Kim JS
• Chung H
• Cho H
• Kim YR
• Ahn JY

• KMID: 2560594
• DOI: http://doi.org/10.3346/jkms.2024.39.e263

Abstract

Background
Patients with hematologic malignancies exhibit persistent severe acute respiratory syndrome coronavirus 2 positivity over long periods after coronavirus disease 2019 (COVID-19) diagnosis. However, the frequency of, risk factors for, and prognosis of prolonged COVID-19 in immunocompromised patients remain unclear. Therefore, we investigated the long-term outcomes of COVID-19 in lymphoma patients and identified the associated factors and impact of prolonged COVID-19 on mortality.
Methods
A multicenter retrospective cohort study of 583 lymphoma patients was conducted in 3 tertiary hospitals in South Korea. Patients receiving lymphoma treatment who were quarantined after obtaining a diagnosis of COVID-19 by polymerase chain reaction (PCR) or antigen test from August 2021 to September 2022 were examined.
Results
Overall, 115 patients (19.7%) were diagnosed with COVID-19. Among 77 patients with clinical data, 24 had prolonged COVID-19. Patients in the prolonged COVID-19 group showed higher rates of receiving rituximab maintenance therapy following bendamustine and rituximab (BR) treatment for follicular lymphoma. This group did not show significant differences in clinical presentation within 30 days of COVID-19 diagnosis; however, it showed higher rates of re-admission due to COVID-19 pneumonia compared with the non-prolonged COVID-19 group. BR treatment followed by rituximab maintenance therapy is one of the risk factors for persistent PCR positivity, delayed or persistent pneumonia, and COVID-19 related admission after quarantine period. Prolonged COVID-19 was an independent risk factor for 1-year mortality.
Conclusion
Prolonged COVID-19 was more frequent in lymphoma patients who received BR treatment followed by rituximab maintenance therapy and associated with unfavorable longterm outcomes and higher 1-year mortality.

Keyword

COVID-19; SARS-CoV-2; Lymphoma; Rituximab; Bendamustine Hydrochloride; Pneumonia; Mortality

Figure

• 

  Fig. 1 Survival probability after COVID-19 diagnosis in lymphoma patients according to the status of prolonged COVID-19.COVID-19 = coronavirus disease 2019.

Reference

1. Duléry R, Lamure S, Delord M, Di Blasi R, Chauchet A, Hueso T, et al. Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol. 2021; 96(8):934–944. PMID: 33909916.

2. Acar IH, Guner SI, Ak MA, Gocer M, Ozturk E, Atalay F, et al. Impact of COVID-19 on outcomes of patients with hematologic malignancies: a multicenter, retrospective study. Mediterr J Hematol Infect Dis. 2022; 14(1):e2022074. PMID: 36425152.

3. Park JM, Koo HY, Lee JR, Lee H, Lee JY. COVID-19 mortality and severity in cancer patients and cancer survivors. J Korean Med Sci. 2024; 39(2):e6. PMID: 38225782.

4. Goldman JD, Robinson PC, Uldrick TS, Ljungman P. COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. J Immunother Cancer. 2021; 9(6):e002630. PMID: 34117116.

5. Shoji K, Suzuki A, Okamoto M, Tsinda EK, Sugawara N, Sasaki M, et al. Prolonged shedding of infectious viruses with haplotype switches of SARS-CoV-2 in an immunocompromised patient. J Infect Chemother. 2022; 28(7):1001–1004. PMID: 35430092.

6. Ueda Y, Asakura S, Wada S, Saito T, Yano T. Prolonged COVID-19 in an immunocompromised patient treated with obinutuzumab and bendamustine for follicular lymphoma. Intern Med. 2022; 61(16):2523–2526. PMID: 35650124.

7. Łyżwa E, Sobiecka M, Lewandowska K, Siemion-Szcześniak I, Barańska I, Klatt M, et al. Prolonged SARS-CoV-2 infection and organizing pneumonia in a patient with follicular lymphoma, treated with obinutuzumab-challenging recognition and treatment. Viruses. 2023; 15(3):693. PMID: 36992402.

8. Lee CY, Shah MK, Hoyos D, Solovyov A, Douglas M, Taur Y, et al. Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies. Cancer Discov. 2022; 12(1):62–73. PMID: 34753749.

9. Jung J, Lee J, Kim SK, Park S, Lim YJ, Kim EO, et al. Evaluation of in-hospital cluster of COVID-19 associated with a patient with prolonged viral shedding using whole-genome sequencing. J Korean Med Sci. 2022; 37(39):e289. PMID: 36217571.

10. Mansour RO, El-Ashwah S, Denewer M. The impact of COVID-19 on acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: a concise review. Blood Res. 2023; 58(1):13–19. PMID: 36774946.

11. Sepulcri C, Dentone C, Mikulska M, Bruzzone B, Lai A, Fenoglio D, et al. The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient-a case study. Open Forum Infect Dis. 2021; 8(11):ofab217. PMID: 34796242.

12. Kos I, Balensiefer B, Roth S, Ahlgrimm M, Sester M, Schmidt T, et al. Prolonged course of COVID-19-associated pneumonia in a B-cell depleted patient after rituximab. Front Oncol. 2020; 10:1578. PMID: 32984017.

13. Levavi H, Lancman G, Gabrilove J. Impact of rituximab on COVID-19 outcomes. Ann Hematol. 2021; 100(11):2805–2812. PMID: 34549309.

14. Ichikawa T, Tamura T, Takahata M, Ishio T, Ibata M, Kasahara I, et al. Prolonged shedding of viable SARS-CoV-2 in immunocompromised patients with haematological malignancies: a prospective study. Br J Haematol. 2024; 204(3):815–820. PMID: 37795527.

15. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Geneva, Switzerland: WHO Press;2008.

16. Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011; 377(9759):42–51. PMID: 21176949.

17. World Health Organization. COVID-19 Clinical Management: Living Guidance, 25 January 2021. Geneva, Switzerland: World Health Organization;2021.

18. Kang SW, Kim JW, Kim JY, Lim SY, Jang CY, Chang E, et al. Characteristics and risk factors of prolonged viable virus shedding in immunocompromised patients with COVID-19: a prospective cohort study. J Infect. 2023; 86(4):412–414. PMID: 36682630.

19. DeWolf S, Laracy JC, Perales MA, Kamboj M, van den Brink MR, Vardhana S. SARS-CoV-2 in immunocompromised individuals. Immunity. 2022; 55(10):1779–1798. PMID: 36182669.

20. Calderón-Parra J, Múñez-Rubio E, Fernández-Cruz A, García-Sánchez MC, Maderuelo-González E, López-Dosil M, et al. Incidence, clinical presentation, relapses and outcome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients treated with anti-CD20 monoclonal antibodies. Clin Infect Dis. 2022; 74(10):1786–1794. PMID: 34383032.

21. Singh N, Madhira V, Hu C, Olex AL, Bergquist T, Fitzgerald KC, et al. Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: a retrospective, nationally sampled cohort study from the U.S. National COVID Cohort Collaborative (N3C). Semin Arthritis Rheum. 2023; 58:152149. PMID: 36516563.

22. Soresina A, Moratto D, Chiarini M, Paolillo C, Baresi G, Focà E, et al. Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatr Allergy Immunol. 2020; 31(5):565–569. PMID: 32319118.

23. Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, et al. CD8⁺ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med. 2021; 27(7):1280–1289. PMID: 34017137.

24. Lyudovyk O, Kim JY, Qualls D, Hwee MA, Lin YH, Boutemine SR, et al. Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses. Cancer Cell. 2022; 40(7):738–753.e5. PMID: 35679859.

25. Lalic H, Aurer I, Batinic D, Visnjic D, Smoljo T, Babic A. Bendamustine: A review of pharmacology, clinical use and immunological effects (Review). Oncol Rep. 2022; 47(6):114. PMID: 35506458.

26. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013; 381(9873):1203–1210. PMID: 23433739.

27. Martínez-Calle N, Hartley S, Ahearne M, Kasenda B, Beech A, Knight H, et al. Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis. Br J Haematol. 2019; 184(6):957–968. PMID: 30548597.

28. Lee CM, Choe PG, Kang CK, Jo HJ, Kim NJ, Yoon SS, et al. Impact of T-cell engagers on COVID-19-related mortality in B-cell lymphoma patients receiving B-cell depleting therapy. Cancer Res Treat. 2023; 56(1):324–333. PMID: 37448122.